ClinicalTrials.gg
CompletedNCT06335303Updated Jul 27, 2026

A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2 interventional study of BI 1819479 and Placebo matching BI 1819479 in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 163 sites in 28 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
322
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim — 1 open to participants now, 3 under way, 1 of them phase 3. Idiopathic Pulmonary Fibrosis · Boehringer Ingelheim.

Enrollment
5th of 18
322 · median 109
Started
2024
with 4 others
Phase 2
7 of 36
1 open now
Registered
31st of 36
by date

Among the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2024, is one of 7 in phase 2, and was the 31st registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study.

Participants are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1819479. Participants in 1 group get placebo. Placebo tablets look like BI 1819479 tablets, but do not contain any medicine. Participants take the treatment for 6 months to 1 year. Participants are in the study for up to 1 year and 2 months. During this time, they visit the study site between 10 and 12 times and get up to 11 phone calls from the site staff.

At site visits doctors regularly perform breathing tests that measure how well the lungs are working. Researchers compare the results between participants who take BI 1819479 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥40 years old at the time of signed .
  2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
  3. Diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
  4. On stable treatment with nintedanib or pirfenidone for at least 12 weeks or not on treatment with either nintedanib or pirfenidone for at least 12 weeks
  5. Forced Vital Capacity (FVC) ≥45% of predicted normal.
  6. Diffusion capacity of the lung for carbon monoxide (DLCO) ≥25% of predicted normal corrected for (Hb).
  7. Women of (WOCBP) must use highly effective methods of with low user dependency and additional barrier contraception for male partners (use of condom) until end of follow-up period.
  8. Male trial participants with WOCBP partners must use contraception (condom) to avoid exposure via seminal fluid. Female partners of male trial participants must use highly effective methods of contraception during treatment until end of follow-up period.

Exclusion criteria

Exclusion Criteria:

  1. Acute exacerbation of Idiopathic Pulmonary Fibrosis (IPF) within at least 12 weeks prior to screening and/or during the screening period (investigator-determined).
  2. Treated with medications (other than oral ) or prednisone >15 mg/day or equivalent for respiratory or pulmonary reasons.
  3. Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
  4. The patient is currently enrolled in another device or drug trial, or their Visit 1 occurs less than 30 days or 5 half-lives (whichever is longer) after completing a previous investigational device or drug trial or receiving other investigational treatments.
  5. Patients with a significant disease or condition other than the IPF under study, which in the opinion of the investigator, may put the patient at risk because of participation, interfere with trial procedures, or cause concern regarding the patient's ability to participate in the trial or any medical condition which could lead to a \<12 months.
  6. Relevant airways obstruction (pre-bronchodilator (FEV1)/forced vital capacity (FVC) \<0.7).
  7. In the opinion of the Investigator, other pulmonary abnormalities.
  8. Lower respiratory tract infection requiring treatment within 4 weeks prior to Visit 1 and/or during the screening period.

Further exclusion criteria apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
322 participants (actual)

Study arms

  • Experimental
    BI 1819479 low dose treatment group

    Drug: BI 1819479

  • Experimental
    BI 1819479 medium dose treatment group

    Drug: BI 1819479

  • Experimental
    BI 1819479 high dose treatment group

    Drug: BI 1819479

  • Placebo comparator
    Placebo group

    Drug: Placebo matching BI 1819479

Interventions

  • BI 1819479

  • DrugPlacebo matching BI 1819479

    Placebo matching BI 1819479

06

What researchers measure

Primary outcomes

  1. Annual rate of decline in Forced Vital Capacity (FVC) [milliLiter/year]

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Absolute change from baseline in FVC at Week 24 [in milliLiter]

    Time frame: At baseline and at week 24

07

Study locations

163 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Critical Care, Pulmonary and Sleep Associates
    Lakewood, Colorado 80228, United States
  • Clinical Research Specialists LLC - Kissimmee
    Kissimmee, Florida 34746, United States
  • SEC Clinical Research
    Pensacola, Florida 32503, United States
  • The Iowa Clinic, PC
    West Des Moines, Iowa 50266, United States
  • Advanced Pulmonary Research
    Warren, Michigan 48088, United States
  • Memorial Hospital Gulfport
    Gulfport, Mississippi 39501, United States
  • Coastal Carolina Health Care, P.A. Pulmonary and Sleep Medicine
    New Bern, North Carolina 28562, United States
  • Southeastern Research Center-Winston Salem-69289
    Winston-Salem, North Carolina 27103, United States
  • Clinical Research Associates of Central PA
    DuBois, Pennsylvania 15801, United States
  • Temple University
    Philadelphia, Pennsylvania 19140, United States
  • Lowcountry Lung and Critical Care
    Charleston, South Carolina 29406, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • Clinical Trials Center of Middle Tennessee, LLC
    Franklin, Tennessee 37067, United States
  • Pulmonary Associates of Richmond, Inc.
    Richmond, Virginia 23230, United States
  • Centro de Investigaciones Metabolicas (CINME)
    C.a.b.a, 1056, Argentina
  • Hospital Britanico de Buenos Aires
    CABA, 1280AEB, Argentina
  • Centro de Investigación Clinica Belgrano
    CABA, 1425, Argentina
  • CEDIC - Centro de Investigacion Clinica
    CABA, C1060ABN, Argentina
  • Consultorios Médicos del Buen Ayre
    Capital Federal, 1425, Argentina
  • Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Launceston Respiratory & Sleep Centre
    Launceston, Tasmania 7250, Australia
  • Lung Research Victoria
    Footscray, Victoria 3011, Australia
  • Austin Hospital
    Heidelberg, Victoria 3084, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Institute for Respiratory Health
    Nedlands, Western Australia 6009, Australia
  • Macquarie University
    Macquarie Park, 2109, Australia
  • Medical University of Graz
    Graz, 8036, Austria
  • Krems University Hospital
    Krems, 3500, Austria
  • Johannes Kepler University Linz
    Linz, 4020, Austria
  • Hospital Elisabethinen Linz
    Linz, Austria
  • Standort Penzing der Klinik Ottakring
    Vienna, 1140, Austria
  • Clinic Floridsdorf
    Vienna, 1210, Austria
  • Klinikum Wels - Grieskirchen GmbH
    Wels, 4600, Austria
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • CHR de la Citadelle
    Liège, 4000, Belgium
  • Serviços Medicos Respirar Sul Fluminense
    Barra Mansa, 27323240, Brazil
  • Faculdade de Medicina de Botucatu - UNESP
    Botucatu, 18618-687, Brazil
  • Hospital das Clínicas da UFG - EBSERH
    Goiânia, 74605-050, Brazil
  • Irmandade da Santa Casa de Misericórdia de Porto Alegre
    Porto Alegre, 90035-074, Brazil
  • Pesquisare
    Santo André, 09080-110, Brazil
  • COE Sao Jose dos Campos
    São José dos Campos, 122241-660, Brazil
  • Hospital Alemao Oswaldo Cruz
    São Paulo, 01327-001, Brazil
  • University of Calgary
    Calgary, Alberta T2N 4Z6, Canada
  • QEII Health Sciences Centre
    Halifax, Nova Scotia B3H 3A7, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
  • McGill University Health Centre (MUHC)
    Montreal, Quebec H4A 3J1, Canada
  • Beijing Chao-Yang Hospital
    Beijing, 100020, China
  • The Second Xiangya Hospital Of Central South University
    Changsha, 410011, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • People's Hospital of Sichuan Province
    Chengdu, 610072, China
  • First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, 510120, China
  • Hangzhou First People's Hospital
    Hangzhou, 310006, China
  • Zhejiang Hospital
    Hangzhou, 310013, China
  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
    Hangzhou, 310016, China
  • Anhui Provincial Hospital
    Hefei, 230001, China
  • Nanjing Drum Tower Hospital
    Nanjing, 210008, China
  • China Shenyang Chest Hospital
    Shenyang, 110000, China
  • Tianjin Medical University General Hospital
    Tianjin, 30052, China
  • Tongji Hospital Affiliated Tongji Medical College Huazhong University of S & T
    Wuhan, 430022, China
  • Affiliated Hospital, Xuzhou Medical college
    Xuzhou, 221009, China
  • University Thomayer´s Hospital
    Prague, 140 59, Czechia
  • University Hospital Bulovka
    Prague, 18081, Czechia
  • Rigshospitalet-København Ø-69883
    København Ø, 2100, Denmark
  • Odense University Hospital
    Odense, 5000, Denmark
  • HYKS Keuhkosairauksien tutkimusyksikkö
    Helsinki, 00029, Finland
  • Oulun yliopistollinen keskussairaala
    Oulu, 90220, Finland
  • Tampereen yliopistollinen sairaala
    Tampere, 33520, Finland
  • TYKS
    Turku, 20520, Finland
  • HOP d'Angers
    Angers, 49933, France
  • HOP Avicenne
    Bobigny, 93000, France
  • Hôpital Louis Pradel
    Bron, 69677, France
  • HOP CHU Caen
    Caen, 14033, France
  • INS Coeur Poumon
    Lille, 59037, France
  • HOP Nord
    Marseille, 13915, France
  • Hopital Pasteur
    Nice, 06001, France
  • HOP Pontchaillou
    Rennes, 35033, France
  • Pneumologische Praxis Dr. Löh
    Bad Homburg, 61350, Germany
  • Charité - Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Universitätsklinikum Bonn AöR
    Bonn, 53127, Germany
  • Caritas-Krankenhaus St. Maria gGmbH
    Donaustauf, 99093, Germany
  • Klinikum Fulda gAG
    Fulda, 36043, Germany
  • Universitätsmedizin Greifswald
    Greifswald, 17475, Germany
  • Klinikum Region Hannover GmbH
    Hanover, 30459, Germany
  • Lungenklinik Hemer
    Hemer, 58675, Germany
  • Lungenfachklinik Immenhausen
    Immenhausen, 34376, Germany
  • Klinikum Konstanz
    Konstanz, 78464, Germany
  • Universität Leipzig
    Leipzig, 04103, Germany
  • Klinikum der Universität München AÖR
    München, 81377, Germany
  • Hospital of Heraklion (PAGNI)
    Crete, 71500, Greece
  • Univ. Gen. Hosp. of Ioannina
    Ioannina, 45 500, Greece
  • University of Debrecen Clinical Centre
    Debrecen, 4032, Hungary
  • A. O. Universitaria Careggi
    Florence, 50137, Italy
  • Ospedale Colonnello D Avanzo
    Foggia, 71100, Italy
  • Ospedale G.B. Morgagni
    Forlì, 47121, Italy
  • Azienda Ospedaliera San Martino
    Genova, 16132, Italy
  • Ospedale Classificato San Giuseppe
    Milan, 20123, Italy
  • Azienda Ospedaliera Universitaria di Padova
    Padova, 35128, Italy
  • Pol. Universitario Tor Vergata
    Roma, 00133, Italy

Showing the first 100 of 163 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Wuyts WA, Bonella F, Ishii H, Lee JS, Renzoni E, Hadl S, Krzykalla J, Stowasser S, Engel M, Molina MM. Design of a phase II randomised, double-blind, placebo-controlled, dose-finding trial of BI 1819479 in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2026 Mar 16;12(2):00973-2025. doi: 10.1183/23120541.00973-2025. eCollection 2026 Mar. PubMed 41846682 ↗

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Nov 2025, 14 months.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 14 months is below that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2024
First posted
Mar 28, 2024
StartActual
Sep 5, 2024
Primary completionActual
Nov 25, 2025
CompletionActual
Jan 16, 2026
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06335303
Responsible party
Sponsor
First posted
Mar 28, 2024
Start date
Sep 5, 2024
Primary completion
Nov 25, 2025
Completion
Jan 16, 2026
Last update
Jul 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI 1819479

Start the discussion